Glenmark Pharmaceuticals Announces Q2FY26 Results

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the second quarter ended September 30, 2025.

Highlights for Q2FY26

- Europe revenue up by 8.5% YoY to Rs. 7,460 Mn
- North America business grew by 7.4% (Net of the out-licensing income of the ISB 2001 deal)
- India Formulations revenue at Rs. 1,650 Mn
- Emerging Markets revenue at Rs. 6,585 Mn
- EBITDA of Rs. 23,596 Mn, up 292% YoY, with an EBITDA margin of 39%.
- Profit After Tax (PAT) of Rs. 6,104 Mn, up 72.2% YoY with PAT margin of 10.1%

For the second quarter of FY 2026, Glenmark's consolidated revenue was at Rs. 60,469 Mn as against Rs. 34,338 Mn in the corresponding quarter last year, recording an increase of 76.1% YoY.

EBITDA was Rs. 23,596 Mn in the quarter ended September 30, 2025, as compared to Rs. 6,019 Mn in the corresponding quarter of the previous year, registering growth of 292% and an EBITDA margin of 39%.

Profit After Tax (PAT) for the quarter was Rs. 6,104 Mn, up 72.2% YoY, with a PAT margin of 10.1%.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the pipeline in a financially self-sustaining way. Across key markets, our performance remained resilient. North America delivered a continued uptick in performance, supported by the expansion of our injectable portfolio and steady execution across institutional channels. Europe returned to its growth trajectory, backed by recent product launches. In India, GST-related adjustments, given our unique three-tiered distribution model, had a one-time impact on primary sales; however secondary sales continue to outperform IPM, and we expect reported growth to normalize from Q3 onwards. "Our specialty and innovation businesses progressed several important milestones this quarter including the global expansion of RYALTRIS®, the UK launch of WINLEVI®, the regulatory and clinical milestones achieved for QiNHAYOTM, and our IGI oncology assets. We remain committed to disciplined execution, advancing meaningful science, and delivering sustained value for our patients, partners, and all stakeholders."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1897.50 as compared to the previous close of Rs. 1876.40. The total number of shares traded during the day was 39916 in over 3138 trades.

The stock hit an intraday high of Rs. 1929.00 and intraday low of 1853.05. The net turnover during the day was Rs. 76016122.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 Q2FY26 H1FY26 ResultUpdate